Shijiazhuang Yiling Group

Shijiazhuang Yiling Pharmaceutical is a leading Chinese pharmaceutical company specializing in the research, development, and manufacturing of Traditional Chinese Medicine (TCM). Founded in 1992 by Academician Wu Yiling, the company operates based on the proprietary "Collateral Disease Theory," which integrates modern medical technology with traditional practices. Its flagship product, Lianhua Qingwen, gained international prominence for its use in treating respiratory viral infections, including COVID-19 and influenza. Beyond TCM, the company has expanded into chemical drugs, health products, and biological medicine, maintaining a robust presence in cardiovascular and cerebrovascular health. The company is listed on the Shenzhen Stock Exchange and operates several large-scale manufacturing bases that meet international GMP standards.